United States Biotechnology & Medical Research

Intra-Cellular Therapies Inc (ITCI)

Track

Ticker: ITCI Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Intra-Cellular Therapies Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 18 Mar 2025
Value US$2,015,078.92 | Price 113.48 | Shares 99,590
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-18 2025-03-18 PrS Proposed sale
ALEXANDRIA VENTURE INVESTMENTS LLC

Director

Non-Executive Director
99,590
113.48
US$2,015,079 		99,590 113.48 US$2,015,079
2025-03-17 2025-03-17 PrS Proposed sale
ALEXANDRIA VENTURE INVESTMENTS LLC

Director

Non-Executive Director
809
60.45
US$3,762,200 		809 60.45 US$3,762,200
2024-12-06 2024-12-05 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
6,918 -36.1%
257.22
US$3,369,086 		6,918 -36.1% 257.22 US$3,369,086
2024-12-06 2024-12-05 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
50,163 -4.5%
84.06
US$4,216,928 		50,163 -4.5% 84.06 US$4,216,928
2024-12-05 2024-12-05 PrS Proposed sale
Mates Sharon

Officer

Officer
51,697
84.02
US$4,343,616 		51,697 84.02 US$4,343,616
2024-12-06 2024-12-04 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
23,333 -2.1%
86.00
US$2,006,750 		23,333 -2.1% 86.00 US$2,006,750
2024-12-06 2024-12-04 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
27,667 -2.5%
85.62
US$2,368,909 		27,667 -2.5% 85.62 US$2,368,909
2024-12-04 2024-12-04 PrS Proposed sale
Mates Sharon

Officer

Officer
51,000
85.73
US$4,372,478 		51,000 85.73 US$4,372,478
2024-11-14 2024-11-13 PlS Planned sale
0.7
Halstead Michael

President

Officer
5,343 -100.0%
88.92
US$475,100 		5,343 -100.0% 88.92 US$475,100
2024-11-14 2024-11-13 PlS Planned sale
0.7
Halstead Michael

President

Officer
13,371 -71.4%
88.17
US$1,178,921 		13,371 -71.4% 88.17 US$1,178,921
2024-11-14 2024-11-12 PlS Planned sale
0.7
Halstead Michael

President

Officer
1,648 -100.0%
90.89
US$149,787 		1,648 -100.0% 90.89 US$149,787
2024-11-14 2024-11-12 PlS Planned sale
0.7
Halstead Michael

President

Officer
6,116 -78.8%
89.63
US$548,177 		6,116 -78.8% 89.63 US$548,177
2024-11-14 2024-11-12 PlS Planned sale
0.7
Halstead Michael

President

Officer
15,105 -66.1%
88.72
US$1,340,116 		15,105 -66.1% 88.72 US$1,340,116
2024-11-12 2024-11-12 PrS Proposed sale
0.7
Halstead Michael

Officer

Officer
41,583
89.08
US$3,704,223 		41,583 89.08 US$3,704,223
2024-09-06 2024-09-06 PrS Proposed sale
ALEXANDRIA VENTURE INVESTMENTS LLC

Director

Non-Executive Director
25,000
73.17
US$1,829,178 		25,000 73.17 US$1,829,178
2024-08-30 2024-08-30 PrS Proposed sale
Mates Sharon

Officer

Officer
34,396
72.78
US$2,503,218 		34,396 72.78 US$2,503,218
2024-08-30 2024-08-30 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
6,193 -0.6%
73.32
US$454,091 		6,193 -0.6% 73.32 US$454,091
2024-08-30 2024-08-30 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
28,203 -2.6%
72.73
US$2,051,261 		28,203 -2.6% 72.73 US$2,051,261
2024-08-30 2024-08-29 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
5,772 -0.5%
73.25
US$422,771 		5,772 -0.5% 73.25 US$422,771
2024-08-30 2024-08-29 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
29,832 -2.7%
72.44
US$2,161,114 		29,832 -2.7% 72.44 US$2,161,114
2024-08-29 2024-08-29 PrS Proposed sale
Mates Sharon

Officer

Officer
35,604
72.51
US$2,581,677 		35,604 72.51 US$2,581,677
2024-08-28 2024-08-28 PrS Proposed sale
Mates Sharon

Officer

Officer
32,699
72.69
US$2,376,774 		32,699 72.69 US$2,376,774
2024-08-28 2024-08-28 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
240 -0.0%
73.70
US$17,688 		240 -0.0% 73.70 US$17,688
2024-08-28 2024-08-28 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
240 -0.0%
73.70
US$17,688 		240 -0.0% 73.70 US$17,688
2024-08-28 2024-08-28 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
32,459 -2.9%
72.74
US$2,361,113 		32,459 -2.9% 72.74 US$2,361,113
2024-08-28 2024-08-28 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
32,459 -2.9%
72.74
US$2,361,113 		32,459 -2.9% 72.74 US$2,361,113
2024-08-28 2024-08-27 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
16,856 -1.6%
73.93
US$1,246,191 		16,856 -1.6% 73.93 US$1,246,191
2024-08-28 2024-08-27 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
16,856 -1.6%
73.93
US$1,246,191 		16,856 -1.6% 73.93 US$1,246,191
2024-08-28 2024-08-27 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
23,657 -2.1%
73.33
US$1,734,865 		23,657 -2.1% 73.33 US$1,734,865
2024-08-28 2024-08-27 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
23,657 -2.1%
73.33
US$1,734,865 		23,657 -2.1% 73.33 US$1,734,865
2024-08-27 2024-08-27 PrS Proposed sale
Mates Sharon

Officer

Officer
40,513
73.52
US$2,978,542 		40,513 73.52 US$2,978,542
2024-08-28 2024-08-26 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
22,713 -2.1%
74.59
US$1,694,229 		22,713 -2.1% 74.59 US$1,694,229
2024-08-28 2024-08-26 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
22,713 -2.1%
74.59
US$1,694,229 		22,713 -2.1% 74.59 US$1,694,229
2024-08-26 2024-08-26 PrS Proposed sale
Mates Sharon

Officer

Officer
22,713
74.53
US$1,692,819 		22,713 74.53 US$1,692,819
2024-08-23 2024-08-23 PrS Proposed sale
Mates Sharon

Officer

Officer
28,680
74.40
US$2,133,656 		28,680 74.40 US$2,133,656
2024-08-23 2024-08-23 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
28,680 -2.6%
74.46
US$2,135,435 		28,680 -2.6% 74.46 US$2,135,435
2024-08-23 2024-08-22 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
4,369 -0.4%
75.47
US$329,727 		4,369 -0.4% 75.47 US$329,727
2024-08-23 2024-08-22 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
35,011 -3.2%
74.58
US$2,611,075 		35,011 -3.2% 74.58 US$2,611,075
2024-08-22 2024-08-22 PrS Proposed sale
Mates Sharon

Officer

Officer
39,380
74.62
US$2,938,358 		39,380 74.62 US$2,938,358
2024-08-23 2024-08-21 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
1,900 -0.2%
77.98
US$148,163 		1,900 -0.2% 77.98 US$148,163
2024-08-23 2024-08-21 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
2,682 -0.2%
77.21
US$207,088 		2,682 -0.2% 77.21 US$207,088
2024-08-23 2024-08-21 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
4,297 -0.4%
76.20
US$327,432 		4,297 -0.4% 76.20 US$327,432
2024-08-23 2024-08-21 PlS Planned sale
Mates Sharon

Chairman and CEO

Executive Director
44,134 -3.9%
75.40
US$3,327,818 		44,134 -3.9% 75.40 US$3,327,818
2024-08-21 2024-08-21 PrS Proposed sale
Mates Sharon

Officer

Officer
53,013
75.59
US$4,007,208 		53,013 75.59 US$4,007,208
2024-08-20 2024-08-16 S Sale
2.0
Neumann Mark

EVP, Chief Commercial Officer

Officer
18,714 -38.7%
75.08
US$1,405,047 		18,714 -38.7% 75.08 US$1,405,047
2024-08-16 2024-08-16 PrS Proposed sale
2.0
Neumann Mark

Officer

Officer
18,714
75.02
US$1,403,972 		18,714 75.02 US$1,403,972
2024-06-25 2024-06-24 S Sale
3.8
RIGGS RORY B
Non-Executive Director
4,462 -3.7%
75.57
US$337,193 		4,462 -3.7% 75.57 US$337,193
2024-06-21 2024-06-18 PlS Planned sale
3.7
VAN NOSTRAND ROBERT L
Non-Executive Director
11,109 -53.4%
76.07
US$845,062 		11,109 -53.4% 76.07 US$845,062
2024-06-21 2024-06-18 PlS Planned sale
3.7
VAN NOSTRAND ROBERT L
Non-Executive Director
8,891 -29.9%
75.71
US$673,138 		8,891 -29.9% 75.71 US$673,138
2024-06-18 2024-06-18 PrS Proposed sale
3.7
VAN NOSTRAND ROBERT L

Director

Non-Executive Director
20,000
75.85
US$1,516,919 		20,000 75.85 US$1,516,919
2024-03-11 2024-03-11 PrS Proposed sale
2.0
Neumann Mark

Officer

Officer
7,345
65.55
US$481,497 		7,345 65.55 US$481,497
2024-03-11 2024-03-11 PrS Proposed sale
0.7
Halstead Michael

Officer

Officer
7,345
65.97
US$484,552 		7,345 65.97 US$484,552
2024-03-11 2024-03-11 PrS Proposed sale
1.2
Hineline Lawrence J.

Officer

Officer
10,121
65.96
US$667,610 		10,121 65.96 US$667,610
2024-03-11 2024-03-11 PrS Proposed sale
Durgam Suresh K.

Officer

Officer
3,712
65.53
US$243,235 		3,712 65.53 US$243,235
2024-03-11 2024-03-11 PrS Proposed sale
Mates Sharon

Officer

Officer
20,565
65.21
US$1,341,103 		20,565 65.21 US$1,341,103
2024-03-11 2024-03-11 PlS Planned sale
Durgam Suresh K.

EVP, Chief Medical Officer

Officer
661 -3.2%
66.96
US$44,261 		661 -3.2% 66.96 US$44,261
2024-03-11 2024-03-11 PlS Planned sale
Durgam Suresh K.

EVP, Chief Medical Officer

Officer
872 -4.1%
65.89
US$57,456 		872 -4.1% 65.89 US$57,456
2024-03-11 2024-03-11 PlS Planned sale
Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,179 -9.3%
65.06
US$141,766 		2,179 -9.3% 65.06 US$141,766
2024-03-11 2024-03-11 PlS Planned sale
2.0
Neumann Mark

EVP, Chief Commercial Officer

Officer
1,313 -4.2%
66.86
US$87,787 		1,313 -4.2% 66.86 US$87,787
2024-03-11 2024-03-11 PlS Planned sale
2.0
Neumann Mark

EVP, Chief Commercial Officer

Officer
1,729 -5.3%
65.92
US$113,976 		1,729 -5.3% 65.92 US$113,976
2024-03-11 2024-03-11 PlS Planned sale
2.0
Neumann Mark

EVP, Chief Commercial Officer

Officer
4,303 -11.6%
65.11
US$280,168 		4,303 -11.6% 65.11 US$280,168
2024-03-11 2024-03-11 PlS Planned sale
Mates Sharon

Chairman, President & CEO

Executive Director
306 -0.0%
67.33
US$20,603 		306 -0.0% 67.33 US$20,603
2024-03-11 2024-03-11 PlS Planned sale
Mates Sharon

Chairman, President & CEO

Executive Director
1,590 -0.2%
66.81
US$106,228 		1,590 -0.2% 66.81 US$106,228
2024-03-11 2024-03-11 PlS Planned sale
Mates Sharon

Chairman, President & CEO

Executive Director
4,128 -0.4%
65.90
US$272,035 		4,128 -0.4% 65.90 US$272,035
2024-03-11 2024-03-11 PlS Planned sale
Mates Sharon

Chairman, President & CEO

Executive Director
14,541 -1.4%
64.80
US$942,257 		14,541 -1.4% 64.80 US$942,257
2024-03-11 2024-03-11 PlS Planned sale
1.2
Hineline Lawrence J.

SVP of Finance, CFO

Officer
64 -100.0%
67.12
US$4,296 		64 -100.0% 67.12 US$4,296
2024-03-11 2024-03-11 PlS Planned sale
1.2
Hineline Lawrence J.

SVP of Finance, CFO

Officer
4,475 -98.6%
66.47
US$297,453 		4,475 -98.6% 66.47 US$297,453
2024-03-11 2024-03-11 PlS Planned sale
1.2
Hineline Lawrence J.

SVP of Finance, CFO

Officer
29 -100.0%
67.32
US$1,952 		29 -100.0% 67.32 US$1,952
2024-03-11 2024-03-11 PlS Planned sale
1.2
Hineline Lawrence J.

SVP of Finance, CFO

Officer
1,100 -97.4%
66.54
US$73,194 		1,100 -97.4% 66.54 US$73,194
2024-03-11 2024-03-11 PlS Planned sale
1.2
Hineline Lawrence J.

SVP of Finance, CFO

Officer
4,453 -79.8%
65.28
US$290,692 		4,453 -79.8% 65.28 US$290,692
2024-03-11 2024-03-11 PlS Planned sale
0.7
Halstead Michael

EVP and General Counsel

Officer
1,238 -100.0%
66.70
US$82,575 		1,238 -100.0% 66.70 US$82,575
2024-03-11 2024-03-11 PlS Planned sale
0.7
Halstead Michael

EVP and General Counsel

Officer
6,107 -83.1%
65.82
US$401,963 		6,107 -83.1% 65.82 US$401,963
2024-03-11 2024-03-07 PlS Planned sale
Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,722 -14.4%
66.86
US$181,993 		2,722 -14.4% 66.86 US$181,993
2024-03-11 2024-03-07 PlS Planned sale
Durgam Suresh K.

EVP, Chief Medical Officer

Officer
3,728 -16.5%
66.34
US$247,316 		3,728 -16.5% 66.34 US$247,316
2024-03-11 2024-03-07 PlS Planned sale
2.0
Neumann Mark

EVP, Chief Commercial Officer

Officer
4,496 -13.1%
66.95
US$301,007 		4,496 -13.1% 66.95 US$301,007
Explore more

More insider trading research around Intra-Cellular Therapies Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America